

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on APRIL 11, 2006
Date

571-273-0698

Signature

SEAN A. PASSINO

Typed or printed name of person signing Certificate

45943

Registration Number, if applicable

202-295-4166

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT
Confirmation no. 3131
Atty. Dkt. No. 087147-0494 (new)
Atty. Dkt. No. 087147-0450 (old)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re reissue application of: U.S. Pat. No. 6,348,481, issued February 19, 2002

Applicants: Yoshiyuki INADA, et al.

Title: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES

Appl. No.: 10/781,263

Filing Date: 02/19/2004

Examiner: Deborah C. Lambkin

Art Unit: 1626

AMENDMENT AND REPLY AFTER NOTICE OF APPEAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper responds to the Final Office action dated August 22, 2005, concerning patent application no. 10/781,263. It is timely, because it was filed within two-months of the Notice of Appeal dated February 22, 2006.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document. **Remarks** begin on page 6 of this document. Please amend the application as follows:

Please endorse

please enter doc

Application No. 10/781,263
 Response to Office action dated August 22, 2005
 Atty. Dkt. No. 087147-0494 (new)
 Atty. Dkt. No. 087147-0450 (old)

NOTICE: THIS APPLICATION IS A REISSUE APPLICATION, AND (i) *Amendments in reissue applications do not fall under 37 CFR § 1.121*: "Any amendment to the description and claims in reissue applications must be made in accordance with § 1.173." 37 CFR § 1.121(i). **Accordingly, do not send a notice alleging that this paper fails to comply with 37 CFR § 1.121.**

1. (Four times amended) A method for the [prophylaxis or] treatment of angiotension II-mediated disease in a mammal in need thereof which comprises administering an effective amount of [at least one of]

(±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate,

2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, or

[2-ethoxyl-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]]-1H-benzimidazole-7-carboxylic acid,]

2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]]-1H-benzimidazole-7-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of furosemide.

JK

2. (Thrice Amended) A method according to claim 1, wherein the disease is hypertension, cardiac insufficiency, ischemic peripheral circulation [disorders] disturbances, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic nephritides, nephritis, arteriosclerosis, hyperaldosteronism, dermatosclerosis, glomerulosclerosis, renal insufficiency, diseases of central nervous system [diseases], sensory [disorders] disturbances [Alzheimer's disease], deficiency of memory, depression, amnesia and senile dementia, anxiety neurosis, catatonia [or indisposition], glaucoma, or intraocular high [pressure] tension.

4. A pharmaceutical composition which comprises at least one of:

Application No. 10/781,263
 Response to Office action dated August 22, 2005
 Atty. Dkt. No. 087147-0494 (new)
 Atty. Dkt. No. 087147-0450 (old)

(±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate,

2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, or

2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

5. The composition of claim 4, in which the compound having diuretic activity is a member selected from the group consisting of amiloride, chlorothiazide, hydrochloride, benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, cyclopentiazide, methyclothiazide, benthylhydrochlorothiazide, penfluthiazide, ethiazide, hydroflumethiazide, polythiazide, chlophenamide, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, tripamide, metrazone, quinethazone, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrylate, piretanide, spironolactone, potassium canrenoate, quinethazone and triamterene.

6. The composition of claim 4, in which the compound having calcium antagonistic activity is a member selected from the group consisting of diltiazem hydrochloride, telordine hydrochloride, nicardipine hydrochloride, varnidipine hydrochloride, flunarizine hydrochloride, verapamil hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and benidipine.

7. A method for treatment of angiotensin II mediated diseases in a mammal in need thereof which comprises administering an effective amount of at least one of

Application No. 10/781,263
 Response to Office action dated August 22, 2005
 Atty. Dkt. No. 087147-0494 (new)
 Atty. Dkt. No. 087147-0450 (old)

(±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate,

2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, or

2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

8. The method of claim 7, in which the angiotensin II-mediated diseases is selected from the group consisting of hypertension, cardiac insufficiency, ischemic peripheral circulation disturbances, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic nephritides, nephritis, arteriosclerosis, hyperaldosteronism, dermatosclerosis, glomerulosclerosis, renal insufficiency, diseases of central nervous system, sensory disturbances, deficiency of memory, depression, amnesia and senile dementia, anxiety neurosis, catatonia, glaucoma and intraocular high tension.

9. The method of claim 7, wherein the compound having diuretic activity is a member selected from the group consisting of amiloride, chlorothiazide, hydrochloride, benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, trichloromethiazide, cyclopentiazide, hydrochlorothiazide, methyclothiazide, benthylhydrochlorothiazide, penfluthiazide, ethiazide, hydroflumethiazide, polythiazide, chlorthalidone, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, triamide, metrazone, indapamide, quinethazone, furosemide, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrylate, piretanide, spironolactone, potassium canrenoate, quinethazone and triamterene.

Application No. 10/781,263
Response to Office action dated August 22, 2005
Atty. Dkt. No. 087147-0494 (new)
Atty. Dkt. No. 087147-0450 (old)

10. The method of claim 7, wherein the compound having calcium antagonistic activity is a member selected from the group consisting of diltiazem hydrochloride, teloridine hydrochloride, nicardipine hydrochloride, varnidipine hydrochloride, flunarizine hydrochloride, verapamil hydrochloride, manidipine hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and benidipine.